DRUG NEWS: Generic versions poised to compete

June 2004 
Volume 34  Number 6
Pages 30 - 30
  PDF Version Available!

© 2004 Lippincott Williams & Wilkins, Inc. Volume 34(6)             June 2004             p 30 Generic versions poised to compete [DRUG NEWS: OXYCONTIN]

The FDA has approved two generic versions of Oxycontin, a 12-hour oral formulation of oxycodone. The move is likely to save money for cancer patients and others who depend on Oxycontin for long-term analgesia.

An effective treatment for prolonged, severe pain, Oxycontin also has a high abuse potential. Intended to be swallowed whole, it causes a fast, dangerous “high” when chewed, injected, or snorted. Highly addictive and linked to more than 100 deaths, it carries the FDA's strongest warning label. The two generic manufacturers, Teva Pharmaceuticals and Endo Pharmaceuticals, will be required to provide the same warnings and safeguards that apply to Oxycontin, which is made by Purdue Pharma.

Patients who need Oxycontin around ...

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events